Abstract
Introduction Coronavirus disease 2019 (COVID-19) has imposed a considerable burden on the United States (US) health system, with particular concern over healthcare capacity constraints.
Methods We modeled the impact of public and private sector contributions to developing diagnostic testing and treatments on COVID-19-related healthcare resource use.
Results We estimated that public sector contributions lead to ≥30% reductions in COVID-19-related healthcare resource utilization. Private sector contributions to expanded diagnostic testing and treatments lead to further reductions in mortality (−44%), intensive care unit (ICU) and non-ICU hospital beds (−30% and −28%, respectively), and ventilator use (−29%). The combination of lower diagnostic test sensitivity and proportions of patients self-isolating may exacerbate case numbers, and policies that encourage self-isolating should be considered.
Conclusion While mechanisms exist to facilitate research, development, and patient access to diagnostic testing, future policies should focus on ensuring equitable patient access to both diagnostic testing and treatments which, in turn, will alleviate COVID-19-related resource constraints.
Competing Interest Statement
Daniel Sheinson, Caroline Solon, William Wong, and Anuj Shah are all salaried employees of Genentech; Mindy Cheng is a salaried employee of Roche Molecular Systems, Inc. David Elsea and Yang Meng received payment from Genentech for consulting fees. Daniel Sheinson, Caroline Solon, William Wong, and Mindy Cheng all hold Roche stock.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All datasets analyzed in this study are publicly available.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analyzed during the current study are available in the COVID Tracking Project repository, https://covidtracking.com/data/api. Programming code used to estimate model parameters is available on Github, https://github.com/Roche/covid-hcru-model.
